Analyst Price Target is $46.67
▲ +221.84% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for UroGen Pharma in the last 3 months. The average price target is $46.67, with a high forecast of $54.00 and a low forecast of $34.00. The average price target represents a 221.84% upside from the last price of $14.50.
Current Consensus is
Buy
The current consensus among 2 contributing investment analysts is to buy stock in UroGen Pharma. This Buy consensus rating has held steady for over two years.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Read More